|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/06/21 Arcadia Biosciences, Inc. 8-K:2 6/29/21 1:27K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 17K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2021
Arcadia Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
|
81-0571538 |
|
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
202 Cousteau Place, Suite 105
(Address of principal executive offices, including zip code)
(530) 756-7077
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common |
RKDA |
NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.01 |
Completion of Acquisition or Disposition of Assets. |
As previously disclosed, on November 12, 2020 Arcadia Biosciences, Inc. (“Arcadia”) acquired 1,875,000 shares of common stock of Bioceres Crop Solutions Corp. (“BIOX Shares”). On June 29, 2021, Arcadia sold 1,562,635 BIOX Shares to 5D+ Draco I Latam Income Plus Segregated Portfolio for a total purchase price of $17,970,303. Arcadia paid a commission for the execution of the transaction in the amount of $250,000 to Roth Capital Partners.
In addition to the foregoing transaction, in the quarter ended June 30, 2021, Arcadia sold a total of 312,365 BIOX Shares in the public market for a total purchase price of $4,125,403. Arcadia paid commissions for the execution of the transactions in the amount of $127,600 to Lake Street Capital Markets. Arcadia no longer holds any BIOX Shares.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ARCADIA BIOSCIENCES, INC. |
|
|
Date: July 6, 2021 |
|
|
|
|
By: |
/s/ Pamela Haley |
|
|
Name: |
|
|
|
Title: |
Chief Financial Officer |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/6/21 | |||
| 6/30/21 | 10-Q, 8-K, 8-K/A | |||
| For Period end: | 6/29/21 | |||
| 11/12/20 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/11/22 Arcadia Biosciences, Inc. 424B3 1:811K Donnelley … Solutions/FA 1/28/22 Arcadia Biosciences, Inc. S-1 6:1.1M ActiveDisclosure/FA |